D Mutimer
Overview
Explore the profile of D Mutimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hann A, Lembach H, Nutu A, Dassanayake B, Tillakaratne S, McKay S, et al.
Br J Surg
. 2022 Feb;
109(4):372-380.
PMID: 35170730
Background: Retransplantation candidates are disadvantaged owing to lack of good-quality liver grafts. Strategies that can facilitate transplantation of suboptimal grafts into retransplant candidates require investigation. The aim was to determine...
2.
Townsend S, Monga M, Nightingale P, Mutimer D, Elsharkawy A, Holt A
Transplant Proc
. 2017 Nov;
49(9):2129-2134.
PMID: 29149973
Introduction: Hepatitis C virus (HCV)-related cirrhosis remains the commonest indication for liver transplantation worldwide, yet few studies have investigated the impact of donation after circulatory death (DCD) graft use on...
3.
Harris R, Martin N, Rand E, Mandal S, Mutimer D, Vickerman P, et al.
J Viral Hepat
. 2016 Mar;
23(8):631-43.
PMID: 27025238
New direct-acting antivirals have the potential to transform the hepatitis C (HCV) treatment landscape, with rates of sustained viral response in excess of 90%. As these new agents are expensive,...
4.
Murthy V, Murray D, Hebballi S, Bramhall S, Lester W, Mutimer D, et al.
Haemophilia
. 2016 Mar;
22(3):e139-44.
PMID: 26931744
Introduction: Patients with hereditary bleeding disorders who have developed end-stage liver disease as a consequence of hepatitis C infection (HCV) acquired from factor concentrates prior to the introduction of viral...
5.
Zeuzem S, Flisiak R, Vierling J, Mazur W, Mazzella G, Thongsawat S, et al.
Aliment Pharmacol Ther
. 2015 Aug;
42(7):829-44.
PMID: 26238707
Background: Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim: To evaluate efficacy and safety of ALV plus...
6.
Armstrong M, Corbett C, Hodson J, Marwah N, Parker R, Houlihan D, et al.
Postgrad Med J
. 2013 Aug;
89(1058):685-92.
PMID: 23924687
Background: Fibroscan is a quick, non-invasive technique used to measure liver stiffness (kPa), which correlates with fibrosis. To achieve a valid liver stiffness evaluation (LSE) the operator must obtain all...
7.
Rowe I, Wilde J, Mutimer D
Haemophilia
. 2012 Aug;
18(5):685-7.
PMID: 22925332
No abstract available.
8.
Wilde J, Mutimer D, Dolan G, Millar C, Watson H, Yee T, et al.
Haemophilia
. 2011 Jun;
17(5):e877-83.
PMID: 21658165
Chronic HCV infection continues to be of significant clinical importance in patients with hereditary bleeding disorders. This guideline provides information on the recent advances in the investigation and treatment of...
9.
Thurairajah P, Khanna A, Mutimer D
J Viral Hepat
. 2010 Nov;
18(11):820.
PMID: 21054684
No abstract available.
10.
Ladoyanni E, Pereira M, Struthers K, Chen K, Haydon G, Mutimer D, et al.
Clin Exp Dermatol
. 2008 Jul;
33(5):655-6.
PMID: 18616727
No abstract available.